JLJianjun Li

Jianjun Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianjun Li has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Kai Ouyang

    Department of Radiotherapy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China

    2 shared publications
  • Manbo Cai

    Department of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China

    2 shared publications
  • Qiao Yang

    Department of Oncology Radiotherapy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China

    2 shared publications
  • Xiaomin Yin

    Department of Radiotherapy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China

    2 shared publications
  • Aixin Li

    Department of Oncology Radiotherapy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China

    1 shared publication
  • Baiwei Zhao

    State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center, Guangzhou 510060, China

    1 shared publication

Latest Publications

  • Open Access

    Unveiling the impact of CDK8 on tumor progression: mechanisms and therapeutic strategies

    by Xiaomin Yin, Zhilong He, Kun Chen, Kai Ouyang, Changxuan Yang, Jianjun Li, Hailin Tang, Manbo Cai

    CDK8 is an important member of the cyclin-dependent kinase family associated with transcription and acts as a key “molecular switch” in the Mediator complex. CDK8 regulates gene expression by phosphorylating transcription factors and can control the transcription process through Mediator complex. Previous studies confirmed that CDK8 is an important oncogenic factor, making it a potential tumor biomarker and a promising target for tumor therapy. However, CDK8 has also been confirmed to be a tumor suppressor, indicating that it not only promotes the development of tumors but may also be involved in tumor suppression. Therefore, the dual role of CDK8 in the process of tumor development is worth further exploration and summary. This comprehensive review delves into the intricate involvement of CDK8 in transcription-related processes, as well as its role in signaling pathways related to tumorigenesis, with a focus on its critical part in driving cancer progression.


  • Open Access

    The dePARylase NUDT16 promotes radiation resistance of cancer cells by blocking SETD3 for degradation via reversing its ADP-ribosylation

    by Weijun Wu, Wenjing Wu, Yingshi Zhou, Qiao Yang, Shuting Zhuang, Caixia Zhong, Wenjia Li, Aixin Li, Wanzhen Zhao, Xiaomin Yin, et al.


  • Open Access

    Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers

    by Yuanfang Li, Baiwei Zhao, Juzheng Peng, Hailin Tang, Sicheng Wang, Sicheng Peng, Feng Ye, Junye Wang, Kai Ouyang, Jianjun Li, et al.


  • Open Access

    Identification and Validation of a Necroptosis-Related Prognostic Signature for Kidney Renal Clear Cell Carcinoma

    by Manbo Cai, Qiao Yang, Junyan He, Haibiao Wu, Zhimin Li, Zhe Fang, Jianjun Li

    Background. Necroptosis is progressively becoming an important focus of research because of its role in the pathogenesis of cancer and other inflammatory diseases. Our study is designed to anticipate the survival time of kidney renal clear cell carcinoma (KIRC) by constructing a prognostic signature of necroptosis-related genes. Materials. Clinical information and RNA-seq data were acquired from Renal Cell Cancer-European Union (RECA-EU) and The Cancer Genome Atlas- (TCGA-) KIRC, respectively. ConsensusClusterPlus was used to identify molecular subtypes, and the distribution of immune cell infiltration, anticancer drug sensitivity, and somatic gene mutations was studied in these subtypes. Subsequently, LASSO-Cox regression and univariate Cox regression were also carried out to construct a necroptosis-related signature. Cox regression, survival analysis, clinicopathological characteristic correlation analysis, nomogram, cancer stem cell analysis, and receiver operating characteristic (ROC) curve were some tools employed to study the prognostic power of the signature. Results. Based on the expression patterns of 66 survival-related necroptosis genes, we classified the KIRC into three subtypes (C1, C2, and C3) that are associated with necroptosis, which had significantly different tumor stem cell components. Among these, C2 patients had a longer survival time and enhanced immune status and were more sensitive to conventional chemotherapeutic drugs. Moreover, in order to predict the prognosis of KIRC patients, five genes (BMP8A, TLCD1, CLGN, GDF7, and RARB) were used to develop a necroptosis-related prognostic signature, which had an acceptable predictive potency. The results from Cox regression and stratified survival analysis revealed that the signature was an independent prognostic factor, whereas the nomogram and calibration curve demonstrated satisfactory survival time prediction based on the risk score. Conclusions. Three molecular subtypes and five necroptosis-related genes were discovered in KIRC using data from TCGA-KIRC and RECA-EU. Thus, a new biomarker and a potentially effective therapeutic approach for KIRC patients were provided in the current study.